Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diltiazem for symptoms of coronary slow flow
IRCT20250415065333N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of diltiazem in Slow Coronary Flow (SCF) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Change in chest pain, Change in functional chest pain status and 2 more. Started Apr 2025; status: completed.
02
Drugs
diltiazem
03
Conditions
Slow Coronary Flow (SCF)
Beyond the preview
Go deeper on IRCT20250415065333N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250415065333N1.